Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: Superiority of doxorubicin

Journal of Clinical Oncology

Volumn 15, Issue 5, 1997, Pages 1897-1905

  Stewart, D J ^a   Evans, W K ^a   Shepherd, F A ^a   Wilson, K S ^a   Pritchard, K I ^a   Trudeau, M E ^a   Wilson, J J ^a   Martz, K ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; MITOXANTRONE;

ADULT; ALOPECIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS;

EID: 0031004468     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.5.1897     Document Type: Article

References (44)

1. Tormey DC, Weinberg VE, Leone LA, et al: A comparison of intermittent v continuous and of Adriamycin v methotrexate 5-drug chemotherapy for advanced breast cancer. A Cancer and Leukemia Group B study. Am J Clin Oncol 7:231-239, 1984
2. Coombes RC, Bliss JM, Wils J, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: Results of a randomized trial. The International Collaborative Cancer Group. J Clin Oncol 14:35-45, 1996
3. Powles TJ, Jones AL, Judson IR, et al: A randomised trial comparing combination chemotherapy using mitomycin-C, mitozantrone and methotrexate with vincristine, anthracycline and cyclophosphamide in advanced breast cancer. Br J Cancer 64:406-410, 1991
4. Smalley RV, Lefante J, Bartolucci A, et al: A comparison of cyclophosphamide, Adriamycin, and 5-fluorouracil and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone in patients with advanced breast cancer. Breast Cancer Treat Res 3:209-220, 1983
5. Carpenter JT, Velez-Garcia E, Aron BS, et al: Five-year results of a randomized comparison of cyclophosphamide, doxorubicin, and fluorouracil v cyclophosphamide, methotrexate and fluorouracil, for node positive breast cancer. Proc Am Soc Clin Oncol 13:A68, 1994 (abstr)
6. Marty M, Bliss JM, Coombes RC, et al: Cyclophosphamide, methotrexate, fluorouracil, v F-epirubicin-C chemotherapy in premenopausal women with node positive breast cancer: Results of a randomized trial. Proc Am Soc Clin Oncol 13:A50, 1994 (abstr)
7. Mauriac L, Durand M, Chauvergne J, et al: Randomized trial of adjuvant chemotherapy for operable breast cancer comparing IV CMF to an epirubicin-containing regimen. Ann Oncol 3:439-443, 1992
8. Fisher B, Brown AM, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483-1496, 1990
9. Mathe G, Misset JL, Plagne R, et al: Adriamycin, vincristine, cyclophosphamide and 5-fluorouracil (AVCF) compared with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in premenopausal breast carcinoma. Personal results. Drug Exp Clin Res 12:143-145, 1986
10. Smith IE: Mitoxantrone: A review of experimental and early clinical studies. Cancer Treat Rev 10:103-115, 1983
11. Cowan JD, Von Hoff DD, Clark GM: Comparative cytotoxicity of Adriamycin, mitoxantrone, and bisantrene as measured by a human tumor cloning system. Invest New Drugs 1:139-144, 1983
12. Yap HY, Blumenschein GR, Schell FC, et al: Dihydroxyanthracenedione: A promising new drug in the treatment of metastatic breast cancer. Ann Intern Med 95:694-697, 1981
13. Mouridsen HT, Cornbleet M, Stuart-Harris R, et al: Mitoxantrone as first-line chemotherapy in advanced breast cancer: Results of a collaborative European study. Invest New Drugs 3:139-148, 1985
14. Landys K, Borgstrom S, Andersson T, et al: Mitoxantrone as a first-line treatment of advanced breast cancer. Invest New Drugs 3:133-137, 1985
15. Smyth JF, Cornbleet MA, Stuart-Harris RC, et al: Mitoxantrone as first-line chemotherapy for advanced breast cancer: Results of a European collaborative study. Semin Oncol 11:15-18, 1984 (suppl 1)
16. Smalley R, Gams R: Phase II study of mitoxantrone in patients with metastatic breast carcinoma: A Southeastern Cancer Study Group project. Cancer Treat Rep 67:1039-1040, 1983
17. Levin M, Pandya KJ, Khandekar JD, et al: Phase II study of mitoxantrone in advanced breast cancer: An Eastern Cooperative Oncology Group pilot study. Cancer Treat Rep 68:1511-1512, 1984
18. Wilson KS, Paterson AHG: First-line mitoxantrone chemotherapy for advanced breast cancer. Cancer Treat Rep 70:1021-1022, 1986
19. Allegra JC, Woodcock T, Woolf S, et al: A randomized trial comparing mitoxantrone with doxorubicin in patients with stage IV breast cancer. Invest New Drugs 3:153-161, 1985
20. Henderson IC, Allegra JC, Woodcock T, et al: Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 7:560-571, 1989
21. Cowan JD, Neidhart J, McClure S, et al: Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: A Southwest Oncology Group study. J Natl Cancer Inst 83:1077-1084, 1991
22. Neidhart JA, Gochnour D, Roach R, et al: A comparison of mitoxantrone and doxorubicin in breast cancer. J Clin Oncol 4:672-677, 1986
23. Crossley RJ: Clinical safety and tolerance of mitoxantrone. Semin Oncol 11:54-58, 1984 (suppl 1)
24. Stewart DJ, Maroun JA, Hirte W, et al: A randomized comparison of cyclophosphamide-mitoxantrone-5-fluorouracil versus cyclophosphamide-doxorubicin-5-fluorouracil in advanced breast cancer: Preliminary observations. Semin Oncol 11:23-27, 1984 (suppl 1)
25. Stewart D, Evans W, Wilson K, et al: Randomized trial cyclophosphamide(C), fluorouracil(F) and doxorubicin(D) or mitoxantrone(M) as first line chemotherapy in advanced breast cancer. Fourteenth International Union Against Cancer Conference Abstracts of Lectures, Symposia & Free Communications, vol 2, p 734, #2824. Budapest, Hungary, August 21-27, 1986
26. Priestman T, Baum M: Evaluation of quality of life in patients receiving treatment for advanced breast cancer. Lancet 1:899, 1976
27. Kaplan EL, Meier P: Non-parametric estimation from incomplete observation. J Am Stat Assoc 53:457-481, 1958
28. Mantel N: Survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
29. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
30. Esteban E, Lacave AJ, Fernandez JL, et al: Phase III trial of cyclophosphamide + epirubicin + fluorouracil (CEF) versus cyclophosphamide + mitoxantrone + fluorouracil (CNF) in women with metastatic breast cancer (MBC). Ann Oncol 5:26, 1994 (abstr; suppl 8)
31. Bennett JM, Muss HB, Doroshow JH, et al: A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. J Clin Oncol 6:1611-1620, 1988
32. Follezou JY, Palangie T, Feuilhade F: Randomized trial comparing mitoxantrone with Adriamycin in advanced breast cancer. Presse Med 16:765-768, 1987
33. Slater J, Green JA, Kelly V: Randomised trial of doxorubicin against mitoxantrone in combination in advanced breast cancer. Proc Eur Conf Clin Oncol 5, 1989 (abstr)
34. Bailey N, Blackledge G, Chetiyawardana A, et al: A controlled randomised study of cyclophosphamide and methotrexate together with either doxorubicin, epirubicin or mitoxantrone in advanced breast cancer. Proc Eur Conf Clin Oncol 5, 1989
35. Haller D, Andersen J, Muggia F, et al: Chemohormone therapy with Adriamycin or mitoxantrone combinations in advanced breast cancer: An Eastern Cooperative Oncology Group trial. Proc Am Soc Clin Oncol 7:19, 1988 (abstr)
36. Leonard RC, Cornbleet MA, Kaye SB, et al: Mitoxantrone versus doxorubicin in combination chemotherapy for advanced carcinoma of the breast. J Clin Oncol 5:1056-1063, 1987
37. Hausmaninger H, Lehnert M, Steger G, et al: Vindesine-epirubicin versus vindesine-mitoxantrone in metastatic breast cancer. Onkologie 12:225-229, 1989
38. Janssens JP, Chin Y, Deleu M, et al: Adriamycin, cyclophosphamide and vindesine versus mitoxantrone, cyclophosphamide and vindesine in advanced breast cancer. Anticancer Res 13:2477-2483, 1993
39. Periti P, Pannuti F, Della Cuna GR, et al: Combination chemotherapy with cyclophosphamide, fluorouracil, and either epirubicin or mitoxantrone: A comparative randomized multicenter study in metastatic breast cancer. Cancer Invest 9:249-255, 1991
40. Taguchi T, Sakai K, Terasawa T, et al: Results of clinical trials with a CMITF (cyclophosphamide, Adriamycin, and 5-fluorouracil) regimen versus a CAF (cyclophosphamide, mitoxantrone, and 5-fluorouracil) regimen in advanced relapsed breast cancer. Jpn J Cancer Chemother 13:2820-2828, 1986
41. Buyukunal E, Derman U, Serdengecti S, et al: A clinical trial of mitoxantrone versus doxorubicin in combination chemotherapy for metastatic breast cancer. Chemioterapia 6:377-379, 1987
42. Heidemann E, Steinke B, Hartlapp J, et al: Randomized clinical trial comparing mitoxantrone with epirubicin and with doxorubicin, each combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer. Onkologie 13:24-27, 1990
43. Alonso MC, Tabernero JM, Ojeda B, et al: A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil versus cyclophosphamide. Adriamycin, and 5-fluorouracil in patients with metastatic breast cancer. Breast Cancer Res Treat 34:15-24, 1995
44. Makuch RW, Johnson MF: Some issues in the design and interpretation of "negative" clinical studies. Arch Intern Med 146:986-989, 1986